Biotechnology in the United Kingdom

Biotechnology in the United Kingdom

Summary

Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the United Kingdom biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

- The biotechnology industry consists of the development, manufacturing, and industrying of products based on advanced biotechnology research.
- The UK biotechnology industry had total revenues of $9.2bn in 2016, representing a compound annual growth rate (CAGR) of 5.7% between 2012 and 2016.
- The medical/healthcare segment was the industry's most lucrative in 2016, with total revenues of $6.1bn, equivalent to 66% of the industry's overall value.
- While growth will remain steady, it will slow slightly and this will result in the UK losing the top spot in Europe over the next five years as Germany’s biotechnology industry overtakes it.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United Kingdom
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United Kingdom
- Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom biotechnology market with five year forecasts

Reasons to buy

- What was the size of the United Kingdom biotechnology market by value in 2016?
- What will be the size of the United Kingdom biotechnology market in 2021?
- What factors are affecting the strength of competition in the United Kingdom biotechnology market?
- How has the market performed over the last five years?
- What are the main segments that make up the United Kingdom's biotechnology market?

Table of Contents
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
AstraZeneca PLC
GE Healthcare
Novartis AG
Sanofi SA
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: United Kingdom biotechnology industry value: $ billion, 2012-16
Table 2: United Kingdom biotechnology industry category segmentation: $ billion, 2016
Table 3: United Kingdom biotechnology industry geography segmentation: $ billion, 2016
Table 4: United Kingdom biotechnology industry value forecast: $ billion, 2016-21
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: GE Healthcare: key facts
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sanofi SA: key facts
Table 13: Sanofi SA: key financials ($)
Table 14: Sanofi SA: key financials (€)
Table 15: Sanofi SA: key financial ratios
Table 16: United Kingdom size of population (million), 2012-16
Table 17: United Kingdom gdp (constant 2005 prices, $ billion), 2012-16
Table 18: United Kingdom gdp (current prices, $ billion), 2012-16
Table 19: United Kingdom inflation, 2012-16
Table 20: United Kingdom consumer price index (absolute), 2012-16
Table 21: United Kingdom exchange rate, 2012-16
List of Figures
Figure 1: United Kingdom biotechnology industry value: $ billion, 2012-16
Figure 2: United Kingdom biotechnology industry category segmentation: % share, by value, 2016
Figure 3: United Kingdom biotechnology industry geography segmentation: % share, by value, 2016
Figure 4: United Kingdom biotechnology industry value forecast: $ billion, 2016-21
Figure 5: Forces driving competition in the biotechnology industry in the United Kingdom, 2016
Figure 6: Drivers of buyer power in the biotechnology industry in the United Kingdom, 2016
Figure 7: Drivers of supplier power in the biotechnology industry in the United Kingdom, 2016
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in the United Kingdom, 2016
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in the United Kingdom, 2016
Figure 10: Drivers of degree of rivalry in the biotechnology industry in the United Kingdom, 2016
Figure 11: AstraZeneca PLC: revenues & profitability
Figure 12: AstraZeneca PLC: assets & liabilities
Figure 13: Novartis AG: revenues & profitability
Figure 14: Novartis AG: assets & liabilities
Figure 15: Sanofi SA: revenues & profitability
Figure 16: Sanofi SA: assets & liabilities